4.3 Article

Paediatric acquired demyelinating syndromes: incidence, clinical and magnetic resonance imaging features

Journal

MULTIPLE SCLEROSIS JOURNAL
Volume 19, Issue 1, Pages 76-86

Publisher

SAGE PUBLICATIONS LTD
DOI: 10.1177/1352458512445944

Keywords

pediatric multiple sclerosis; paediatric multiple sclerosis; acute disseminated encephalomyelitis; demyelination; demyelinating; pediatric; paediatric; childhood; adolescent; epidemiology; incidence; magnetic resonance imaging

Funding

  1. Multiple Sclerosis Society UK [893/08]
  2. Action Medical Research [SP4472]
  3. Wellcome Trust [GN79832]
  4. MS Society
  5. Action Medical Research charities
  6. Eli Lilly
  7. Wyeth
  8. SHS
  9. Teva
  10. Merck Serono
  11. Bayer
  12. Euroimmun
  13. UCB
  14. Biogen Idec
  15. Shire
  16. Merck Sereno
  17. Novartis
  18. Genzyme
  19. Action Medical Research [1746] Funding Source: researchfish

Ask authors/readers for more resources

Objective: Changing trends in multiple sclerosis (MS) epidemiology may first be apparent in the childhood population affected with first onset acquired demyelinating syndromes (ADSs). We aimed to determine the incidence, clinical, investigative and magnetic resonance imaging (MRI) features of childhood central nervous system ADSs in the British Isles for the first time. Methods: We conducted a population active surveillance study. All paediatricians, and ophthalmologists (n = 4095) were sent monthly reporting cards (September 2009-September 2010). International Paediatric MS Study Group 2007 definitions and McDonald 2010 MS imaging criteria were used for acute disseminated encephalomyelitis (ADEM), clinically isolated syndrome (CIS) and neuromyelitis optica (NMO). Clinicians completed a standard questionnaire and provided an MRI copy for review. Results: Card return rates were 90%, with information available for 200/222 positive notifications (90%). After exclusion of cases, 125 remained (age range 1.3-15.9), with CIS in 66.4%, ADEM in 32.0% and NMO in 1.6%. The female-to-male ratio in children older than 10 years (n = 63) was 1.52: 1 (p = 0.045). The incidence of first onset ADS in children aged 1-15 years old was 9.83 per million children per year (95% confidence interval [CI] 8.18-11.71). A trend towards higher incidence rates of ADS in children of South Asian and Black ethnicity was observed compared with White children. Importantly, a number of MRI characteristics distinguished ADEM from CIS cases. Of CIS cases with contrast imaging, 26% fulfilled McDonald 2010 MS diagnostic criteria. Conclusions: We report the highest surveillance incidence rates of childhood ADS. Paediatric MS diagnosis at first ADS presentation has implications for clinical practice and clinical trial design.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available